AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Ligand Pharmaceuticals Incorporated
Video analysis: LGND
All videosNo video analysis for this stock yet. Request one from our team.
News: LGND
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity.
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m.
Handelsbanken Fonder AB Raises Stake in Ligand Pharmaceuticals Incorporated $LGND
Handelsbanken Fonder AB boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 22.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,358 shares of the biotechnology company's stock after purchasing an additional 1,900 shares during the quarter.
Ligand Pharmaceuticals Q2 Earnings Call Highlights
Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 27.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,564 shares of the biotechnology company's stock after selling 5,472 shares during the period.
Ashford Capital Management Inc. Has $41.44 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND
Ashford Capital Management Inc. reduced its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 207,565 shares of the biotechnology company's stock after selling 6,213 shares during the quarter. Ligand Pharmaceuticals makes
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026.
